131 related articles for article (PubMed ID: 2557300)
1. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
McGuire WP; Blessing JA; Berman ML
Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
McGuire WP; Blessing JA; Yordan E; Beecham J
Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
Vaughn CB; Salmon SE; Fleming TR
Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
[TBL] [Abstract][Full Text] [Related]
6. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
[TBL] [Abstract][Full Text] [Related]
7. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
[TBL] [Abstract][Full Text] [Related]
8. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
[TBL] [Abstract][Full Text] [Related]
9. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
Hochster H; Hunt M; Green M; Parkinson D; Smith T
Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial with 4'-deoxydoxorubicin (esorubicin).
Rozencweig M; Crespeigne N; Kenis Y
Invest New Drugs; 1983; 1(4):309-13. PubMed ID: 6678877
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
Green MD; Speyer JL; Wernz JC; Colombo N; Beller U; Muggia FM; Beckman EM
Invest New Drugs; 1990 Aug; 8(3):333-6. PubMed ID: 2272774
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
Fiore J; Kemeny N; Raymond V; Young C
Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
[No Abstract] [Full Text] [Related]
14. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Rose PG; Blessing JA; Lele S; Abulafia O
Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.
Falkson G; Vorobiof DA
Invest New Drugs; 1986; 4(2):165-9. PubMed ID: 3733376
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.
Eitan R; Fishman A; Meirovitz M; Goldenberg H; Amit A; Koren C; Schneider Y; Rosengarten O; Neuman A; Keren-Rosenberg S; Safra T
Anticancer Drugs; 2014 Jan; 25(1):101-5. PubMed ID: 24263191
[TBL] [Abstract][Full Text] [Related]
20. Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.
van Oosterom AT; Aapro MS; Carnino F; van der Burg ME; Pecorelli S; Rotmensz N; Dalesio O; Vermorken JB
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1379-80. PubMed ID: 3181261
[No Abstract] [Full Text] [Related]
[Next] [New Search]
